The oral vaccination against Fowlpox was investigated via drinking water containing the F132-c strain of Fowlpox virus to be effective even though the vaccine virus-titer was 10 4 TCID 50 /dose each time. When the virus-titer of the F132-c strain was 10 4-5 TCID 50 /dose per single drinking water vaccination, 90% or more of chickens were not protected, however, they were protected when vaccinated twice via drinking water. A weak immune response occurred by a slight infection after the first vaccination, and due to memory cells, a booster could work well after the second vaccination. These results suggest the possibility of reducing both the amount of virus required for a vaccine via drinking water and the labor cost in the field. KEY WORDS: Fowlpox virus, oral vaccination.
Fowlpox (FP) is an infective disease often occurring among domestic fowls and other birds all over the world. When domestic fowls are infected with Fowlpox virus (FPV), growth retardation, respiratory signs, abnormalities in egg production and a rise in mortality are observed. FP infection results in economic losses in the poultry industry. However, serious problems have not been reported since live vaccines have been employed in most farms and FP infection has been well controlled. The FP vaccine is usually administered via the wing web or subcutaneously, once for broilers or twice for layers. However, procedures for vaccination are time-consuming and require a lot of manpower. Therefore, if a new vaccine is developed that can be administered via drinking water, substantial decreases in labor will be expected. Vaccination methods by which a vaccine virus is administered to the upper respiratory tract via aerosol, via oral administration intratracheally, drinking water or food peletts against FP have previously been reported by Mayer and Danner [3] and others [1, 2, 5, 6] . However, compared to the wing web vaccine, a 100-to 1000-fold vaccine virus titer was necessary to obtain satisfactory immunization. A high virus-titer/dose will not be acceptable since manufacturing vaccine in such a large scale will be difficult and expensive. Menesse suggested that to make this technique feasible, selecting the adequate vaccine strain was crucial [4] .
In the present study, we first showed that vaccination against FP via drinking water containing the F132-c strain of FPV was effective, even though the vaccine virus-titer was 10 4 TCID 50 /dose each time, which at least 1/100 lower than previously reported [3] .
Chickens: Specific pathogen-free chickens 42 days old were obtained from the Chemo-Sero-Therapeutic Research Institute. The chickens were divided into groups and reared separately in isolated rooms.
Viruses: The F132-c strain of FPV, obtained by threetime plaque cloning on a chicken embryo fibroblast (CEF) culture from Nisigahara F132 strain, was supplied by Kyoritsu Seiyaku Corporation (Tokyo), courtesy of Dr. Y. Fujikawa. The F132-c strain was propagated in CEF culture within two passages before use. The FPV Nisigahara strain was used as a challenge virus. A commercial live fowlpox virus vaccine (Poxine strain) manufactured by Kyoto Biken Laboratories, Inc. (Kyoto) was purchased.
Vaccination procedure: Each experiment was conducted in 10 chickens in each group. Three different series of experiments were done in this study.
In experiment 1 (Table 1) , 42-day-old chickens were randomly divided into 4 groups. Groups 1 and 2 were vaccinated orally with 10 5 and 10 6 TCID 50 /doses of F132-c strain respectively, through a mouth-catheter. Group 3 was vaccinated with a commercial vaccine via the wing web at a 10 3 TCID 50 /dose, and group 4 served as the unvaccinated control. Experiment 2 ( Table 2 ) was carried out to examine the route and times of vaccination, using 6 groups. Groups 1 and 2 were orally vaccinated with a 10 5 TCID 50 /dose of the F132-c strain through a mouth-catheter, and groups 3 and 4 received the virus via drinking water. The chickens in groups 3 and 4 were not allowed to drink water for four hours, then given 10 ml of water containing a 10 5 TCID 50 / dose of the F132-c strain for each chicken. Groups 1 and 3 were vaccinated at 42 days of age, and groups 2 and 4 were vaccinated twice at 42 and 56 days of age. Group 5 was vaccinated with a commercial vaccine via the wing web at 42 days of age, and group 6 was the unvaccinated control.
The virus-titer/dose was changed in experiment 3 ( Table  3 ). All groups in experiment 3 were vaccinated via drinking water except for the control groups (groups 7 and 8). Groups 1 and 2 were vaccinated with a 10 4 TCID 50 /dose, groups 3 and 4 with a 10 5 TCID 50 /dose, and groups 5 and 6 with a 10 6 TCID 50 /dose. Group 7 was vaccinated with a commercial vaccine via the wing web and group 8 was the unvaccinated control. Groups 1, 3, 5, and 7 were vaccinated with the virus at 42 days of age, and groups 2, 4, and 6 were vaccinated twice, at 42 and 56 days of age.
Challenge procedure: All chickens were challenged at 70 days of age. The challenge was conducted by feather follicle inoculation. Briefly, the feathers were removed from an area 3 × 3 cm on the thigh. 10 4 TCID 50 /bird of the Nisiga-hara strain was dropped on the thigh and brushed gently with a small toothbrush. The chickens were observed daily for lesions on the challenge region. The lesions only developing pocks were regarded as "protected" and developing ulcers were regarded as "not protected".
Indirect immunofluorescent antibody (IFA) test: An anti- body for FPV was checked by IFA test. Chicken blood was drawn at the challenge and used for a serum sample. The FPV F132-c strain was inoculated into CEF monolayer culture on cover slips in a petri-dish. Three days later, the cover slips were fixed in acetone and stored at -80°C until use. Sera were diluted by 1:160 in phosphate-buffered saline (PBS), poured on fixed-cell cover slips, and reacted for one hour at 37°C. Then, after washing with PBS, the cover-slips were reacted with fluorescein-conjugated IgG fraction rabbit anti-chicken IgG (Cappel Laboratory) for one hour at 37°C. After washing, specific fluorescence was observed under a microscope. The results of experiment 1 are shown in Table 1 . There were no obvious abnormal clinical signs due to oral vaccination. Two chickens out of ten orally vaccinated with 10 5 TCID 50 /dose had antibodies at the challenge and developed a very small lesion upon challenge, which were assessed as protected (group 1). However, eight chickens developed typical pox-infected lesions. Nine out of ten chickens orally vaccinated with 10 6 TCID 50 /dose were antibody-positive at the challenge, and all chickens, including one chicken that was antibody negative, showed protection against the challenge (group 2). Chickens vaccinated via the wing web produced typical pocks that resembled vaccine "takes" at the site of vaccination, but no other clinical signs were observed. All chickens vaccinated via the wing web produced antibody at the challenge and were protected against the challenge (group 3). All unvaccinated control chickens were antibody-negative and developed severe typical pox lesions upon challenge.
The results of experiment 2 are shown in Table 2 . Chickens orally vaccinated with a 10 5 TCID 50 /dose were not protected against the challenge even when vaccinated twice (groups 1 and 2). However, in group 4, inoculated twice via drinking water, all chickens were protected and had the antibodies at the challenge. In the single vaccination group 3, only one chicken was protected.
The results of experiment 3 are shown in Table 3 . When the vaccinated virus-titer was 10 6 TCID 50 /dose, all chickens were protected, whether vaccinated once or twice (groups 5 and 6). When the virus-titer was 10 5 TCID 50 /dose or 10 4 TCID 50 /dose by single vaccination, more than 90% of chickens were not protected against the challenge and none of them had antibodies (groups 1 and 3). However, more than 90% of chickens were protected and more than 70% of chickens had antibodies when they were vaccinated twice (groups 2 and 4).
Single oral vaccination with the F132-c strain required a virus titer of 10 6 TCID 50 /dose to provide the same protection level as vaccination via the wing web with a commercial vaccine against FPV challenge. This is a virus-titer 1,000 times higher than the commercial wing web vaccine. The virus titer of 10 6 TCID 50 /dose is as high as the titer obtained when the virus is cultured in CEF or on the chorio-allantoicmembrane of embryo chicken eggs. Therefore, the viruscultured solution must be concentrated to produce a feasible vaccine. Considering the cost of the concentration proce-dure, a vaccine containing a virus titer of 10 6 TCID 50 /dose is not economically acceptable.
Since single vaccination was not effective at 10 5 TCID 50 / dose, in experiment 2, vaccination twice with an appropriate interval was attempted and a more practical method to vaccination via drinking water was investigated. Although groups 2 and 4 were vaccinated with the same dose and times, the results differed by the vaccine administration route suggesting a different mechanism of immunization between oral inoculation and inoculation via drinking water. When chickens were inoculated with FPV via drinking water, the upper respiratory tract might be exposed to the virus much longer compared to oral route. Therefore, vaccination via drinking water may be more efficient for viral infection than the oral route of vaccination. In the case of the oral inoculation, the respiratory mucosa of the chicken would be only briefly exposed to the vaccine virus, especially when inoculated with a small amount of virus. With a single inoculation via drinking water, chickens were not protected; however, by a double inoculation via drinking water, a good immune response was obtained, equivalent to the wing web vaccine. It could be possible that a certain weak response of the immune system may have occurred by a slight infection induced after the first inoculation, and due to memory cells, a booster could work well after the second inoculation. Experiment 3 shows the success of a low virus titer (10 4 TCID 50 /dose) vaccination if inoculated twice, suggesting the efficacy of a vaccination via drinking water.
In all experiments, the IFA positive ratio was highly correlated with the protection ratio, showing a correlation coefficient of 0.994. Therefore, antibody reactions may be useful in estimating the immune status of vaccinated chickens.
In this study, chickens were protected by a vaccination twice via drinking water containing the F132-c strain, even at a 10 4 TCID 50 /dose. Mayer and Danner [3] reported vaccination to FP via drinking water was effective, although they needed a high virus-titer as 10 7 TCID 50 /dose. At this moment there is no satisfactory explanation for the discrepancy between the present result and theirs. However, there may be a difference in tissue affinity to the virus of respiratory mucosa. The vaccine virus titer used in drinking water vaccination which was only about 10-fold higher than the virus-titer of the present wing web vaccine, is a reasonable quantity for a manufactured vaccine, and is expected to reduce the labor cost in the field.
There were no clinical signs or gross lesions in the tracheal mucosa or skin in any of the groups vaccinated with the F132-c strain via drinking water. It is considered that double vaccinations with the F132-c strain via drinking water would be safe for 42-day-old chickens; however, when the F132-c strain was given orally through a mouthcatheter into a mouth to one-week-old chickens, they developed pox on their wattle and showed open breathing (unpublished). This observation may suggest the possibility that vaccination via drinking water is not also safe for very young chickens. Recently, the in ovo vaccination to FP is available. Therefore, vaccination to FP will not always be needed for one-week-old chickens or younger, and FP vaccine containing F132-c strain also will not be needed for younger chickens irrespective of the administration route. However, a second vaccination to FP is still reqired and vaccination via wing web requires more labor than the first vaccination at a young age. Therefore, vaccination via drinking water could be useful in administering the second vaccination at 42 days of age or older.
